MORINAGA M-16V | JAPAN Bifidobacterium breve, M-16V This human strain probiotic is widely used, including Neonatal Intensive Care Units (NICU) in more than 140 hospitals in Japan, Australia, and Singapore, for underweight infant health. It offers the potential in protecting against premature birth complications and allergies. Clinical studies demonstrate the combined use of B. breve M-16V and B. longnum BB536 to be capable of reducing eczema, improving intestinal barrier function, boosting immunity, and reducing inflammation. High stability and survival rate, from specialized inoculation technology and production process from Morinaga.

Leave a Reply

Your email address will not be published. Required fields are marked *